Newbury Pharmaceuticals AB Cash Flow-to-Debt Ratio
Newbury Pharmaceuticals AB cash flow-to-debt ratio. Newbury Pharmaceuticals AB (NEWBRY) has a Cash Flow-to-Debt Ratio of 0.05x as of February 2026, meaning its operating cash flow of Skr2.26 Million could theoretically repay 0% of its total liabilities (Skr45.96 Million) in one year. Check Newbury Pharmaceuticals AB earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Newbury Pharmaceuticals AB (2021–2024)
Cash flow-to-debt ratio of Newbury Pharmaceuticals AB from 2021 to 2024. Historical debt coverage capacity for Newbury Pharmaceuticals AB across 4 annual periods. Check Newbury Pharmaceuticals AB (NEWBRY) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Newbury Pharmaceuticals AB Cash Flow-to-Debt Ratio by Year (2021–2024)
Newbury Pharmaceuticals AB cash flow-to-debt ratio by year from 2021 to 2024. Year-by-year debt coverage analysis for Newbury Pharmaceuticals AB. For the full cash flow conversion analysis, see Newbury Pharmaceuticals AB (NEWBRY) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.61x | Skr-23.71 Million | Skr38.95 Million | ▲ +38.3% |
| 2023 | -0.99x | Skr-23.23 Million | Skr23.54 Million | ▼ -19.3% |
| 2022 | -0.83x | Skr-15.00 Million | Skr18.14 Million | ▲ +11.7% |
| 2021 | -0.94x | Skr-4.07 Million | Skr4.34 Million | — |